ZFYVE21

Across TCGA pan-cancer cohorts, ZFYVE21 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZFYVE21 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZFYVE21 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFYVE21 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

OV, PDAC, and CCRCC are the cancer types where ZFYVE21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.636	1.000	.007	16	view →
PDAC	OS	Tertile	IV	0.973	0.490	.024	11	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	5	view →
LUAD	OS	Median	II,III,IV	0.371	0.833	.003	5	view →
HNSC	OS	Quartile	IV	0.844	1.000	.029	4	view →
GBM	OS	Quartile	All	0.693	0.349	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZFYVE21–OV (DFS)

Open the OV breakdown →